Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis : A post hoc analysis of a multicentre, open-label, randomised, parallel-group study
© Japan College of Rheumatology 2024. Published by Oxford University Press..
OBJECTIVES: To clarify changes in serum cytokines, chemokines, and bone-related factors during denosumab treatment in rheumatoid arthritis (RA) patients.
METHODS: This was a post hoc analysis of a multicentre, open-label, randomised, parallel-group study. Patients were randomly assigned to continue treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) plus receive treatment with denosumab (csDMARDs plus denosumab group) or to continue treatment with csDMARD therapy alone for 12 months. Serum biomarker levels were measured at baseline and 6 and 12 months.
RESULTS: Baseline and 6-month data from the csDMARDs plus denosumab (n = 22) and csDMARD therapy alone (n = 22) groups were analysed. Statistically significant changes from baseline were seen: dickkopf-related protein 1 decreased at 6 and 12 months (both groups); osteopontin decreased at 6 months in the csDMARDs plus denosumab group; osteopontin and soluble CD40 ligand increased at 6 and 12 months in the csDMARD therapy alone group; osteocalcin decreased at 6 and 12 months, epidermal growth factor decreased at 12 months, and macrophage-derived chemokine decreased at 6 months in the csDMARDs plus denosumab group; and interferon gamma-induced protein-10 increased at 12 months in the csDMARD therapy alone group.
CONCLUSIONS: Denosumab may inhibit bone destruction by suppressing bone-related factors/chemokines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Modern rheumatology - (2024) vom: 13. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Iwamoto, Naoki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Revised 16.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/mr/roae002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367170361 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367170361 | ||
| 003 | DE-627 | ||
| 005 | 20240116232139.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240116s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/mr/roae002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1261.xml |
| 035 | |a (DE-627)NLM367170361 | ||
| 035 | |a (NLM)38226481 | ||
| 035 | |a (PII)roae002 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Iwamoto, Naoki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis |b A post hoc analysis of a multicentre, open-label, randomised, parallel-group study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © Japan College of Rheumatology 2024. Published by Oxford University Press. | ||
| 520 | |a OBJECTIVES: To clarify changes in serum cytokines, chemokines, and bone-related factors during denosumab treatment in rheumatoid arthritis (RA) patients | ||
| 520 | |a METHODS: This was a post hoc analysis of a multicentre, open-label, randomised, parallel-group study. Patients were randomly assigned to continue treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) plus receive treatment with denosumab (csDMARDs plus denosumab group) or to continue treatment with csDMARD therapy alone for 12 months. Serum biomarker levels were measured at baseline and 6 and 12 months | ||
| 520 | |a RESULTS: Baseline and 6-month data from the csDMARDs plus denosumab (n = 22) and csDMARD therapy alone (n = 22) groups were analysed. Statistically significant changes from baseline were seen: dickkopf-related protein 1 decreased at 6 and 12 months (both groups); osteopontin decreased at 6 months in the csDMARDs plus denosumab group; osteopontin and soluble CD40 ligand increased at 6 and 12 months in the csDMARD therapy alone group; osteocalcin decreased at 6 and 12 months, epidermal growth factor decreased at 12 months, and macrophage-derived chemokine decreased at 6 months in the csDMARDs plus denosumab group; and interferon gamma-induced protein-10 increased at 12 months in the csDMARD therapy alone group | ||
| 520 | |a CONCLUSIONS: Denosumab may inhibit bone destruction by suppressing bone-related factors/chemokines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a chemokines | |
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a denosumab | |
| 650 | 4 | |a rheumatoid arthritis | |
| 700 | 1 | |a Sato, Shuntaro |e verfasserin |4 aut | |
| 700 | 1 | |a Furukawa, Kaori |e verfasserin |4 aut | |
| 700 | 1 | |a Michitsuji, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Shiraishi, Kazuteru |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Kounosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Chiba, Ko |e verfasserin |4 aut | |
| 700 | 1 | |a Osaki, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakami, Atsushi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Modern rheumatology |d 2000 |g (2024) vom: 13. Jan. |w (DE-627)NLM162086628 |x 1439-7609 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:13 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/mr/roae002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 13 |c 01 | ||